title: CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure.
abstract: BACKGROUND
  Inhibition of myocardial fatty acid oxidation has been suggested as a therapeutic approach for improving cardiac function in chronic heart failure (HF). The novel piperazine derivative CVT-4325 was shown to inhibit fatty acid oxidation in cardiac mitochondria and in isolated perfused rat hearts. In the present study, we tested the hemodynamic and metabolic effects of acute intravenous CVT-4325 in dogs with HF.
  
  
  RESULTS
  HF (LV ejection fraction <or=35%) was created in eight dogs by multiple sequential intracoronary microembolizations. Treatment with CVT-4325 administered intravenously as 0.5 mg/kg bolus followed by a continuous infusion of 0.8 mg/kg/h for 40 min reduced free fatty acid (FFA) uptake (4.51+/-0.96 to 1.65+/-0.32 micromols/min, p<0.04), coronary blood flow (56+/-3 to 46+/-4 ml/min, p<0.01), and myocardial oxygen consumption (MVO2) (240+/-23 to 172+/-7 micromols/min, p<0.03), and increased LV ejection fraction (30+/-2 to 37+/-1%, p<0.0001). In the same study, but on a different day, the same dogs were treated with an inactive analogue of CVT-4325 (CVT-2540), and no hemodynamic or metabolic effects were observed.
  
  
  CONCLUSIONS
  In dogs with HF, acute intravenous infusion of CVT-4325 reduces FFA uptake and improves LV systolic function without increasing MVO2. The improvement in LV systolic function in the absence of an increase in MVO2 and a lower FFA uptake is consistent with the concept that inhibition of myocardial fatty acid oxidation may be an effective treatment for HF.
authors.affiliation: Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, MI, USA.
authors.forename: Makoto
authors.initials: M
authors.lastname: Imai
authors.forename: Sharad
authors.initials: S
authors.lastname: Rastogi
authors.forename: Naveen
authors.initials: N
authors.lastname: Sharma
authors.forename: Margaret P
authors.initials: MP
authors.lastname: Chandler
authors.forename: Victor G
authors.initials: VG
authors.lastname: Sharov
authors.forename: Brent
authors.initials: B
authors.lastname: Blackburn
authors.forename: Luiz
authors.initials: L
authors.lastname: Belardinelli
authors.forename: William C
authors.initials: WC
authors.lastname: Stanley
authors.forename: Hani N
authors.initials: HN
authors.lastname: Sabbah
mesh_terms: D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D004285:Dogs; D005227:Fatty Acids / Q000378:metabolism* / Q000493:pharmacokinetics; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D007275:Injections, Intravenous; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism*; D010069:Oxadiazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects*; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013318:Stroke Volume / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: C524583:CVT 2540; D005227:Fatty Acids; D010069:Oxadiazoles; D010879:Piperazines; C499690:para-trifluoro-methyl-5-phenyl-1,2,4-oxadiazole